Related Experiment Video
Updated: Aug 13, 2025
Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
Published on: September 27, 2024
Effective decolonization strategy for mupirocin-resistant Staphylococcus aureus by TPGS-modified mupirocin-silver
Ming-Chen Sun1,2, Ying-Fang Chen3, Di Liu2
1Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, 310014, China.
A novel d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) modified mupirocin and silver complex (TPGS/Mup-Ag) effectively combats mupirocin-resistant Staphylococcus aureus (MuRSA). This innovative approach significantly reduces required mupirocin concentration and promotes wound healing.
Area of Science:
- Nanotechnology in Medicine
- Antimicrobial Resistance Research
- Drug Delivery Systems
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global health concern.
- Emergence of mupirocin-resistant Staphylococcus aureus (MuRSA) necessitates novel therapeutic strategies.
- Existing treatments face challenges due to increasing antibiotic resistance.
Purpose of the Study:
- To develop a TPGS-modified mupirocin and silver complex (TPGS/Mup-Ag) to combat MuRSA.
- To evaluate the efficacy of TPGS/Mup-Ag against antibiotic-resistant bacteria.
- To explore the potential of silver-based bactericides for resistant infections.
Main Methods:
- Synthesis of d-α-tocopherol polyethylene glycol 1000 succinate (TPGS) modified mupirocin and silver complex (TPGS/Mup-Ag).
- Characterization of particle size and antibacterial activity of TPGS/Mup-Ag.
- In vitro and in vivo models to assess efficacy in bacterial infection and wound healing.
Main Results:
- TPGS modification resulted in small particle size (∼16 nm), enhancing bacterial internalization.
- TPGS/Mup-Ag demonstrated synergistic antibacterial activity, reducing effective mupirocin concentration by approximately 60-fold.
- In vivo studies showed effective inhibition of skin infection, accelerated wound healing, and reduced systemic inflammation.
Conclusions:
- TPGS/Mup-Ag is a promising therapeutic agent against mupirocin-resistant Staphylococcus aureus.
- The developed complex effectively eliminates intracellular bacteria and inhibits adhesion without affecting host cells.
- This study provides a foundation for developing advanced therapeutic agents for antibiotic-resistant bacteria.
